Category: Gastric cancer

Home / Established Year

Pembrolizumab with chemotherapy is approved by the USFDA for HER2-negative gastric or gastroesophageal junction adenocarcinoma

Pembrolizumab with chemotherapy is approved by the USFDA for HER2-negative gastric or gastroesophageal junction adenocarcinoma

The Food and Drug Administration approved pembrolizumab (Keytruda, Merck) in combination with fluoropyrimidine- and platinum-containing chemotherapy on November 16, 2023. This approval is for the initial treatment of adults with ..

FDA revises pembrolizumab's indication for gastric cancer

FDA revises pembrolizumab’s indication for gastric cancer

The Food and Drug Administration updated the approved use of pembrolizumab (Keytruda, Merck) in combination with trastuzumab, fluoropyrimidine, and platinum-containing chemotherapy for treating HER2-positive gastric or gastroeso..

,

Nivolumab has been approved by the FDA for resected esophageal or gastroesophageal junction cancer

August 2021: The FDA has approved Nivolumab (Opdivo, Bristol-Myers Squibb Company) for patients with fully resected oesophagus or gastroesophageal junction (GEJ) cancer who have received neoadjuvant chemoradiotherapy and have pers..

, , , , ,

Pembrolizumab receives accelerated approval from the FDA for HER2-positive gastric cancer

August 2021: Pembrolizumab (Keytruda, Merck & Co.) in combination with trastuzumab, fluoropyrimidine-, and platinum-containing chemotherapy has been granted accelerated approval by the Food and Drug Administration for the firs..

, , , , ,

Nivolumab in addition to chemotherapy is approved by FDA for metastatic gastric cancer and esophageal adenocarcinoma

August 2021: For advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma, the Food and Drug Administration approved nivolumab (Opdivo, Bristol-Myers Squibb Company) in conjunction wit..

, , , , , ,

Pembrolizumab has been approved by the FDA for the treatment of esophageal or gastroesophageal junction cancer

August 2021: Pembrolizumab (Keytruda, Merck Sharp & Dohme Corp.) in combination with platinum and fluoropyrimidine-based chemotherapy has been approved by the Food and Drug Administration for patients with metastatic or locall..

, , , ,

Pembrolizumab approved for use in any cancer with a high tumor mutational burden

July 2021: The US Food and Medication Administration (FDA) has expanded the indications for pembrolizumab (Keytruda), an immunotherapy drug, to encompass any cancer with a high mutational burden (TMB-H). The new authorization is f..

Easily adoptable methods to improve outcomes in treatment of gastroesophageal cancers

July 9th 2021: During the European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2021, two scientists from Roswell Park Comprehensive Cancer Center were asked to share new findings on the treatment ..

Lonsurf
, , , ,

Lonsurf is approved by FDA for recurrent, metastatic gastric and gastroesophageal junction adenocarcinoma

Trifluridine/tipiracil tablets (LONSURF, Taiho Pharmaceutical Co., Ltd.) were approved by the Food and Drug Administration on February 22, 2019 for adult patients with metastatic gastric or gastroesophageal junction (GEJ) adenocar..

, , , , , , , ,

CAR T-Cell therapy approvals and availability

July 2021:  In June 2014, KITE Biotechnology Company, with only 19 employees, was listed on NASDAQ in the United States, and it took 130 million US dollars in one day! Just two months later, Juno Biotechnology had less than 20 em..

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, Gene therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) CAR T-Cell therapy
2) Gene therapy
3) Gamma-Delta T Cell therapy
4) TIL therapy
5) NK Cell therapy